The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies
Signed inform consent
Histolgically verified solid tumour
Receiving systemic therapy for neoplasm
Has archival tumour tissue
Concurrent Lymphoprolipherative disorder
Patients after stem cell or bone marrow thansplantation
Incomplete informaton on previous cancer history or medical history
Patients with known primary immunodeficiency
The study will include patients with solid tumours receiving systemic therapy for their disease who do not have other significant factors that affect the immune system
Cohort
Prospective
Not listed
7
Trial groupsSee each trial group below.
Progression in 3 mo
Presence of disease progression within 3 mo from sample aquisition
Overall survival (OS)
Time from sample aquisition to death from any reason
Progression free survival
Time from sample aquisition to progression or death from the disease
Response rate
Response assesmenr with RECIST 1.1 and iRECIST
Click on the lead sponsor to view all of their trials.
